| Colorectal Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.82 |
| Chemotherapy |
0 |
0.73 |
| Immunotherapy |
0 |
0.99 |
| Metastatic Colorectal Cancer |
0 |
0.45 |
| Microsatellite Instability-High |
0 |
0.31 |
| Microsatellite Instability |
0 |
0.22 |
| Breast Cancer |
0 |
0.19 |
| Hepatocellular Carcinoma |
0 |
0.18 |
| Metastasis |
0 |
0.18 |
| Targeted Cancer Therapy |
0 |
0.18 |
| Pituitary Gland |
0 |
0.16 |
| Cancer |
0 |
0.15 |
| Texas |
0 |
0.15 |
| Toxicology |
0 |
0.15 |
| Breast |
0 |
0.13 |
| Diarrhea |
0 |
0.12 |
| Adrenal Insufficiency |
0 |
0.07 |
| Angiogenesis Inhibitors |
0 |
0.07 |
| Biomarker |
0 |
0.07 |
| Cardiomyopathy |
0 |
0.07 |
| Colitis |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.07 |
| Gland |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Hepatitis |
0 |
0.07 |
| Hepatitis A |
0 |
0.07 |
| Humanized Monoclonal Antibody |
0 |
0.07 |
| Inflammatory Bowel Disease |
0 |
0.07 |
| KRAS |
0 |
0.07 |
| Liver |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Monoclonal Antibody |
0 |
0.07 |
| Myocarditis |
0 |
0.07 |
| Utah |
0 |
0.07 |